$CNCE News

Last published 1y ago

1y agoCNCE INCYConcert Pharmaceuticals, Inc. vs Incyte Corporation - AIA Trial, DismissedUS Patent Trial and Appeal Board
2y agoCNCE INCYConcert Pharmaceuticals, Inc. vs Incyte Corporation - AIA Trial, AffirmedUS Patent Trial and Appeal Board
3y agoCNCEConcert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia AreataBusiness WireConcert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its
3y agoANGN AQUA CNCE KERNMoore Kuehn Encourages KERN, CNCE, AQUA and ANGN Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoANGN CNCE NVCN VLTAMoore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law FirmPR NewswireNEW YORK, Jan. 21, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
3y agoCNCESun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia AreataPR NewswireAdds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to
3y agoCNCESun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia AreataBusiness WireAdds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to
3y agoCNCEConcert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair ResearchBusiness WireNew Analyses Presented on the Effect of Baseline Severity and Duration of Current Episode of Hair Loss on Scalp Hair Regrowth Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the presentation of data from
4y agoCNCEConcert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT. A webcast of the
4y agoCNCEConcert Pharmaceuticals Reports Third Quarter 2022 Financial ResultsBusiness WireCompany Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News
4y agoCNCEConcert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022Business WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will
4y agoCNCEConcert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV CongressBusiness Wire35 Percent of Patients Treated With CTP-543 12 mg Twice-Daily Achieved At Least 90 Percent Scalp Hair Coverage (SALT Score ≤ 10) After 24 Weeks of Treatment Newly-Reported Results Show Significant Improvement in Eyebrow and Eyelash Regrowth in Pati
4y agoCNCEConcert Pharmaceuticals to Present at H.C. Wainwright Global Investment ConferenceBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022. Th
4y agoCNCEBridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia AreataBusiness WireSeptember is Alopecia Areata Awareness Month Alopecia Areata is a Serious Autoimmune Disorder with Limited Treatment Options In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be
4y agoCNCEConcert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV CongressBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at th
4y agoCNCEConcert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing ArrangementBusiness WireExercise Relates to Remaining Tranche 1 Warrants Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that BVF Partners L.P. and RA Capital Management have exercised their remaining tranche 1 warrants issued in connection with the Company's No
4y agoCNCEConcert Pharmaceuticals Reports Second Quarter 2022 Financial ResultsBusiness WireCTP-543 Positive Topline Results Reported in THRIVE-AA1 and THRIVE-AA2 Phase 3 Studies in Alopecia Areata CTP-543 Has the Potential to Address an Important Unmet Need for a Large, Underserved Patient Population Conference Call Scheduled Today at
4y agoCNCEConcert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia AreataBusiness WireTHRIVE-AA2 Study Met Primary Endpoint for Scalp Hair Regrowth Key Secondary Endpoint Met for Patient Reported Outcome on Hair Satisfaction Key Secondary Endpoint Met for Hair Regrowth as Early as 12 Weeks CTP-543 Has Potential to be Best-in-Cla
4y agoCNCEConcert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022Business WireNew Online Registration Required for Live Call to Ask Questions Audio-Only Webcast Still Available on Concert's Website Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the second quarter of
4y agoCNCEStudy to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects - NCT05478772ClinicalTrials.govCmax, Tmax, λz, (and 4 more...)
4y agoCNCEStudy to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543 - NCT05468749ClinicalTrials.govSingle dose PK exposure: Maximum observed concentration (Cmax), Single dose PK exposure: Area Under the Concentration-Time Curve from time zero to the time of the last observed/measured non-zero concentration (AUC0-t), Single dose PK exposure: Area Under the Concentration-Time Curve from time 0 extrapolated to infinity (AUC0-inf), Assessment of Safety and Tolerability following administration of C ...
4y agoCNCEStudy to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543 - NCT05467722ClinicalTrials.govSingle dose PK exposure: Maximum observed concentration (Cmax), Single dose PK exposure: Area Under the Concentration-Time Curve from time zero to the time of the last observed/measured non-zero concentration (AUC0-t), Single dose PK exposure: Area Under the Concentration-Time Curve from time 0 extrapolated to infinity (AUC0-inf), Assessment of Safety and Tolerability following administration of C ...
4y agoCNCEStudy To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects - NCT05467709ClinicalTrials.govCmax, Tmax, AUC0-inf, (and 6 more...)
4y agoCNCEStudy of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers - NCT05467696ClinicalTrials.govBioavailability and Pharmacokinetic Profile of CTP-543: Cmax, Bioavailability and Pharmacokinetic Profile of CTP-543: Tmax, Bioavailability and Pharmacokinetic Profile of CTP-543: AUC(0-Tlast), (and 6 more...)
4y agoCNCEConcert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences ConferenceBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY. A webcast of the JMP fireside chat may be accesse
4y agoCNCEPhase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of DermatologyBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the publication of safety and efficacy data from the randomized, double-blind, placebo-controlled dose-ranging Phase 2 clinical trial for CTP‑543 in the Journal of the American Academy of Der
4y agoCNCEConcert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of WarrantsBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share. The aggregate gross proceeds to Concert from this
4y agoCNCEConcert Pharmaceuticals Announces Pricing of Public OfferingBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $4.75 per share. The gross proceeds to Concert, before deducting underwriti
4y agoCNCEConcert Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Concert. The offering
4y agoCNCEConcert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia AreataBusiness WireTHRIVE-AA1 Study Meets Primary Endpoint for Scalp Hair Regrowth and Key Secondary Endpoints at Both Doses Statistically Significant Hair Regrowth Observed as Early as Eight Weeks CTP-543 Has Potential to be Best-in-Class for the Treatment of Alope
4y agoCNCEConcert Pharmaceuticals Reports First Quarter 2022 Financial ResultsBusiness WirePhase 3 Data Readout in Alopecia Areata Expected Second Quarter of 2022 Alopecia Areata Represents Significant Market Opportunity with Important Medical Need Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:
4y agoCNCEConcert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022Business WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at
4y agoCNCEConcert Pharmaceuticals Reports 2021 Financial Results and Provides Company UpdateBusiness WireTwo Phase 3 Registrational Clinical Trials Fully Enrolled for CTP-543 for the Treatment of Alopecia Areata CTP-543 THRIVE-AA1 Phase 3 Trial Topline Data Expected Second Quarter of 2022 CTP-543 THRIVE-AA2 Phase 3 Trial Topline Data Expected Third Q
4y agoCNCEConcert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022Business WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast
4y agoCNCEA Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers - NCT05192369ClinicalTrials.govTQT Analysis
4y agoCNCEConcert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia AreataBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has completed patient enrollment in THRIVE-AA2, the second Phase 3 clinical trial to evaluate the efficacy and safety of CTP‑543, an oral Janus kinase (JAK) inhibitor, in adult patien
4y agoCNCEConcert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual ConferenceBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January
5y agoCNCEConcert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare ConferencesBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate in a virtual fireside chat at The Jefferies London Healthcare Conference. The on-demand fireside chat will be available beginning at 8:00 a.m. GMT on November 18, 2021.
5y agoCNCEConcert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company UpdateBusiness WireCTP-543 THRIVE-AA1 Phase 3 Trial in Patients with Moderate to Severe Alopecia Areata Fully Enrolled with Topline Data Expected Second Quarter of 2022 CTP-543 THRIVE-AA2 Phase 3 Trial in Patients with Moderate to Severe Alopecia Areata Progressing wit
5y agoCNCEConcert Pharmaceuticals, inc (CNCE) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsCNCE earnings call for the period ending September 30, 2021.
5y agoCNCE EVAX GOGO MAXR+1Thinking about buying stock in Evaxion Biotech, Stratasys, Maxar Technologies, Concert Pharmaceuticals, or Gogo?PR NewswireNEW YORK, Nov. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVAX, SSYS, MAXR, CNCE, and GOGO.
5y agoCNCEConcert Pharmaceuticals Announces $65 Million FinancingBusiness WireFinancing Provided by Leading Healthcare Funds BVF Partners L.P. and RA Capital Management Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has entered into an agreement with BVF Partners L.P. (BVF) and RA Capital Management (RA) t
5y agoCNCEConcert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021Business WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the third quarter of 2021, on Tuesday, November 9, 2021, before the U.S. financial markets open. The Company will host a conference call and webcas
5y agoCNCEConcert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia AreataBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has completed patient enrollment in THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP‑543, an oral Janus kinase (JAK) inhibitor, in adult patient
5y agoCNCEEuropean Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata - NCT05041803ClinicalTrials.govNumber of Participants with Adverse Events as a Measure of Safety, Effect of CTP-543 on treating hair loss as measured by the Severity of Alopecia Tool (SALT)
5y agoCNCEConcert Pharmaceuticals to Present at Upcoming Investor ConferencesBusiness WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate virtually at the following upcoming investor conferences: The H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, on-demand beginning a
5y agoCNCELandmarks and Bridges Will Illuminate Blue Throughout the Month of September for Alopecia Areata Awareness MonthBusiness WireIn recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this important autoimmune disease. The effort will unite U.S. cities in observation of
5y agoCNCEConcert Pharmaceuticals Reports Second Quarter 2021 Financial ResultsBusiness WireCTP-543 Phase 3 Program On Track to Support NDA Filing in Early 2023 Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the second quarter of 2021. "Our development p
5y agoCNCEConcert Pharmaceuticals, inc (CNCE) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsCNCE earnings call for the period ending June 30, 2021.
5y agoCNCEConcert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021Business WireConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the second quarter of 2021, on Thursday, August 5, 2021, before the U.S. financial markets open. The Company will host a conference call and webcas